Naltrexone and Alcoholism Treatment
Multiple Choice
1. Executive Summary and Recommendations
Naltrexone has been approved as an adjunct to psychosocial treatment and should not be seen as a replacement for psychoso 2. Patients requiring narcotic analgesia are suitable candidates for naltrexone treatment.
3. Naltrexone interferes with nonopiod pain medications such as as ibuprofen, acetaminophen, and aspirin.
4. The Consensus Panel recommends that patients be abstinent for how many days before initiating naltrexone treatment?
A 3-7 days
C 10-20 days
B 5-10 days
D 15-30 days
5. What percent of patients experience adverse effects at the initiation of naltrexone treatment?
6. Chapter 1 - The Current Situation
What percent of the national health care budget do alcoholics consume?
A 5%
7. The abuse of alcohol and other substances can cause profound changes in brain chemistry and function. Understanding of th
stigma and shame surrounding repeated relapse to alcohol abuse.
A True
8. Chapter 2 - Pharmacological Management with Naltrexone
When starting a patient on naltrexone treatment, which of the following should be considered a part of eligibility determinat A Dosing strategies
C Concurrent psychosocial intervention
B Medical considerations
D All of the above
9. Naltrexone has been proven to be an effective replacement to psychosocial treatment of alcoholism.
10. The daily cost of treatment with naltrexone is approximately:
A $2.00 per day
C $6.50 per day
B $4.50 per day
D $8.00 per day
11. Reduction in drinking resulting from treatment combining Naltrexone therapy may lead to improved liver function.
12. For what drug is Naltrexone contraindicated in patients who are addicted and have not yet withdrawn?
A Methamphetamines
C Marijuana
B Opiates
D None of the above
13. There is no withdrawal syndrome associated with naltrexone therapy, therefore the usual daily dose may be discontinued wi
14. Chapter 3 - Basic Neurobiological and Preclinical Research
Advances in neurobiological research has helped to establish addiction as a biological brain disease that is relapsing and chr 15. The fundamental functional unit of the nervous system is a specialized cell called a:
A Macrophage
16. Within a neuron, signals are carried via:
A Neurotransmitters
C Electrical Impulses
B Hormones
D None of the above
17. Chemical messengers that transmit signals between neurons are neurotransmitters.
18. Pleasure inducing action that becomes repetitive is called:
A Positive reinforcement
C Natural reinforcement
B Negative reinforcement
D None of the above
19. Unlike many other drugs of abuse (such as opiates, etc.), alcohol acts upon a specific receptor in the brain.
20. Endogenous opiods, a class of neuropeptides, produce what is know as the “runner’s high” and also reduce sensitivity to pai
21. Both animal and human studies have shown alcohol to increase levels of GABA.
22. This neurotransmitter is the primary inhibitor of the central nervous system:
A Dopamine
C Glutamate
B Serotonin
23. Men with alcoholic fathers are how many times more likely than men without any family history of alcoholism to experienc
A 3-5 times
C 10-12 times
B 5-8times
D 20-30 times
24. Chapter 4 - Clinical Findings
Naltrexone is the first medication approved by the FDA for the treatment of alcohol dependence in nearly 50 years.
A True
25. The most impressive result from the studies done with naltrexone were significantly reduced rates of relapse.
26. The average age of subjects participating in most studies of naltrexone is:
A early 30’s
C late 50’s
B early 40’s
D late 20’s
27. Chapter 5: Clinical Profile
Naltrexone was approved by the FDA in December of:
A 1990
28. By binding to opiod receptor sites within the central nervous system, naltrexone prevents the stimulation of opiod receptors.
29. The mean elimination half-life value for naltrexone is:
D None of the above
30. One of the most serious potential adverse effects of naltrexone is kidney toxicity.

Source: http://www.quantumunitsed.com/materials/0728_Naltrexone%20and%20Alcoholism%20Treatment.pdf


We have the pleasure to invite you to the EAGE postgraduate course: Recent Advances in Clinical Gastroenterology that will take place in Belgrade, Serbia on Sunday March 25, 2007. The programme will include broad range of topics and a prestigious list of international faculty. List of topics includes session on therapeutic choices in patients with dys-pepsia and GERD. A session dealing with


use of synthetic antimicrobial peptides to facilitate the our laboratory identified molecules having the ability to boost the effectiveness of anti-infective agents. these molecules have themselves anti-infective properties (antibacterial and antifungal) and are able to increase the effectiveness of antibiotics already commercially available. We study the effect of different synthetic peptides

© 2010-2014 Pdf Medical Search